Quantum Genomics launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension Quantum Genomics launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension Read the press realease Previous Post (p) Delpharm Group selected for large-scale production of firibastat tablets Next Post (n) Orient EuroPharma (OEP) acquires a stake in Quantum Genomics
